Anika Therapeutics (STU:AKP) Cyclically Adjusted Book per Share: €17.35 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:AKP Anika Therapeutics Inc STU:AKP
69 GF Score
Price €13.80
GF Value €17.92
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Anika Therapeutics Cyclically Adjusted Book per Share?

Anika Therapeutics STU:AKP +2.22% 69 Cyclically Adjusted Book per Share is €17.35 as of Mar. 2026. GuruFocus rates STU:AKP with a GF Score™ of 69/100 and a GF Value™ of €17.92 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Anika Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was €8.671. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €17.35 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Anika Therapeutics's average Cyclically Adjusted Book Growth Rate was -0.70% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 2.40% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 6.90% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Anika Therapeutics was 14.60% per year. The lowest was 2.40% per year. And the median was 12.85% per year.

As of today (2026-07-16), Anika Therapeutics's current stock price is €13.80. Anika Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €17.35. Anika Therapeutics's Cyclically Adjusted PB Ratio of today is 0.80.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Anika Therapeutics was 6.72. The lowest was 0.40. And the median was 2.50.


Anika Therapeutics  (STU:AKP) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Anika Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=13.80/17.35
=0.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Anika Therapeutics was 6.72. The lowest was 0.40. And the median was 2.50.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Anika Therapeutics Cyclically Adjusted Book per Share Related Terms


Anika Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Anika Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anika Therapeutics Cyclically Adjusted Book per Share Chart

Anika Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.04 17.20 17.97 19.01 16.64

Anika Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.90 17.29 16.70 16.64 17.35

STU:AKP vs LFCR, DERM, ASRT: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Anika Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anika Therapeutics Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anika Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Anika Therapeutics's Cyclically Adjusted PB Ratio falls into.


STU:AKP
69GF Score
Anika Therapeutics Inc STU:AKP
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anika Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Anika Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=8.671/330.2130*330.2130
=8.671

Current CPI (Mar. 2026) = 330.2130.

Anika Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 12.311 241.018 16.867
201609 13.072 241.428 17.879
201612 14.438 241.432 19.747
201703 14.676 243.801 19.878
201706 14.824 244.955 19.984
201709 14.494 246.819 19.391
201712 15.159 246.524 20.305
201803 14.508 249.554 19.197
201806 14.474 251.989 18.967
201809 15.394 252.439 20.137
201812 16.306 251.233 21.432
201903 16.753 254.202 21.762
201906 16.111 256.143 20.770
201909 17.925 256.759 23.053
201912 18.140 256.974 23.310
202003 18.720 258.115 23.949
202006 18.033 257.797 23.099
202009 16.997 260.280 21.564
202012 15.627 260.474 19.811
202103 16.176 264.877 20.166
202106 16.510 271.696 20.066
202109 17.079 274.310 20.560
202112 17.594 278.802 20.838
202203 17.874 287.504 20.529
202206 18.544 296.311 20.666
202209 19.702 296.808 21.919
202212 18.432 296.797 20.507
202303 17.588 301.836 19.242
202306 17.256 305.109 18.676
202309 17.315 307.789 18.576
202312 13.277 306.746 14.293
202403 12.945 312.332 13.686
202406 13.168 314.175 13.840
202409 11.029 315.301 11.551
202412 10.201 315.605 10.673
202503 9.576 319.799 9.888
202506 8.880 322.561 9.091
202509 8.673 324.800 8.818
202512 8.821 324.054 8.989
202603 8.671 330.213 8.671

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €17.35 mean?
Anika Therapeutics (STU:AKP) has a Cyclically Adjusted Book per Share of €17.35 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Anika Therapeutics and its competitors.
Is Anika Therapeutics' Cyclically Adjusted Book per Share too high?
Anika Therapeutics' current Cyclically Adjusted Book per Share is €17.35. Overall, Anika Therapeutics has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anika Therapeutics' Cyclically Adjusted Book per Share compare to LFCR and DERM?
Anika Therapeutics' Cyclically Adjusted Book per Share of €17.35 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Anika Therapeutics and its competitors. Anika Therapeutics's current Cyclically Adjusted Book per Share is €17.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anika Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Anika Therapeutics (STU:AKP) is currently considered Modestly Undervalued. The stock's GF Value™ is €17.92, compared to a current price of €13.80 — trading 23% below its estimated fair value. The current Cyclically Adjusted Book per Share is €17.35. Anika Therapeutics' overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Anika Therapeutics (STU:AKP), the current Cyclically Adjusted Book per Share is €17.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anika Therapeutics (STU:AKP) Overvalued in 2026?

Based on GuruFocus' analysis, Anika Therapeutics stock appears to be undervalued. The current stock price of €13.80 is trading 23% below its estimated GF Value™ of €17.92. GuruFocus considers Anika Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:AKP:

  • Cyclically Adjusted Book per Share: €17.35
  • GF Value™: €17.92 vs. price of €13.80 (23% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the STU:AKP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Anika Therapeutics Business Description

Other Exchanges ANIK:USA
Address 32 Wiggins Avenue, Bedford, MA, USA, 01730
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
69GF Score

Get the complete analysis for STU:AKP

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.80
Price
€17.92
GF Value